Cargando…
Targeted therapy or immunotherapy? Optimal treatment in hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is the fifth leading cause of cancer mortality in the United States and the second leading cause of cancer mortality worldwide. Sorafenib is the only food and drug administration (FDA) approved as first line systemic treatment in HCC. Regorafenib and nivolumab are the...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Baishideng Publishing Group Inc
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5952267/ https://www.ncbi.nlm.nih.gov/pubmed/29770170 http://dx.doi.org/10.4251/wjgo.v10.i5.108 |